Overexpression of Fn14 promotes androgen-independent prostate cancer progression through MMP-9 and correlates with poor treatment outcome.

Fibroblast growth factor-inducible 14 (Fn14), a transmembrane receptor binding to the multifunctional cytokine tumor necrosis factor-like weak inducer of apoptosis (TWEAK), is known to modulate many cellular activities including cancer progression. Here, we demonstrated the significant role of Fn14 in invasion, migration and proliferation of androgen-independent prostate cancer (AIPC) cells. Fn14 and its ligand TWEAK were highly expressed in two AIPC cell lines, DU 145 and PC-3, whereas expression was weak in androgen-sensitive LNCaP cells. Fn14 knockdown using small-interfering RNAs attenuated migration, invasion and proliferation and enhanced apoptosis in the AIPC cell lines. Both forced overexpression of Fn14 by stable Fn14 complementary DNA transfection to PC-3 cells (PC-3/Fn14) and ligand activation by recombinant TWEAK in PC-3 cells enhanced invasion. Fn14 was shown to modulate expression of matrix metalloproteinase (MMP)-9, and MMP-9 mediated the invasive potential influenced by Fn14 in PC-3 cells. In vivo, subcutaneous xenografts of PC-3/Fn14 grew significantly faster than xenograft of PC-3/Mock, and the invasive capacity in PC-3/Fn14 was found to be higher than that of PC-3/Mock as evaluated in an invasion model of the diaphragm. Furthermore, the messenger RNA expressions of MMP-9 in PC-3/Fn14 xenografts were significantly higher than those in PC-3/Mock xenografts. Clinically, high expression of Fn14 was significantly associated with higher prostate-specific antigen recurrence rate in patients who underwent radical prostatectomy. In conclusion, the overexpression of Fn14 may contribute to multiple malignant cellular phenotypes associated with prostate cancer (PCa) progression, in part via MMP-9. TWEAK-Fn14 signaling may be a novel therapeutic target of PCa.

[1]  N. Kyprianou,et al.  Anoikis and survival connections in the tumor microenvironment: is there a role in prostate cancer metastasis? , 2005, Cancer research.

[2]  C. Sheehan,et al.  Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  T. Zheng,et al.  TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. , 2007, Cytokine.

[4]  C. Gialeli,et al.  Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting , 2011, The FEBS journal.

[5]  Dominique Trudel,et al.  An immunohistochemical study , 2013 .

[6]  L. Klotz,et al.  Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. , 2007, Journal of the National Cancer Institute.

[7]  Kristen R. Ross,et al.  The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. , 2003, The American journal of pathology.

[8]  J. Winkles.  The TWEAK–Fn14 cytokine–receptor axis: discovery, biology and therapeutic targeting , 2008, Nature Reviews Drug Discovery.

[9]  S. Tyagi,et al.  Tumor Necrosis Factor-related Weak Inducer of Apoptosis Augments Matrix Metalloproteinase 9 (MMP-9) Production in Skeletal Muscle through the Activation of Nuclear Factor-κB-inducing Kinase and p38 Mitogen-activated Protein Kinase , 2009, Journal of Biological Chemistry.

[10]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[11]  K. Yanaga,et al.  Nafamostat mesilate can prevent adhesion, invasion and peritoneal dissemination of pancreatic cancer thorough nuclear factor kappa-B inhibition , 2011, Journal of hepato-biliary-pancreatic sciences.

[12]  A. Whittemore,et al.  Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. , 1995, Journal of the National Cancer Institute.

[13]  S. Ybarra,et al.  Antibodies to TWEAK Receptor Inhibit Human Tumor Growth through Dual Mechanisms , 2010, Clinical Cancer Research.

[14]  C. F. Harris,et al.  Immune function, mitogenicity, and angiogenic growth factor concentrations in lean and obese rodent sera: implications in obesity-related prostate tumor biology , 2003, Prostate Cancer and Prostatic Diseases.

[15]  Liying Gu,et al.  TWEAK promotes ovarian cancer cell metastasis via NF-kappaB pathway activation and VEGF expression. , 2009, Cancer letters.

[16]  Liang Cheng,et al.  Nuclear Factor-κB Is Constitutively Activated in Prostate Cancer In vitro and Is Overexpressed in Prostatic Intraepithelial Neoplasia and Adenocarcinoma of the Prostate , 2004, Clinical Cancer Research.

[17]  T. Habuchi,et al.  Candidate genes involved in enhanced growth of human prostate cancer under high fat feeding identified by microarray analysis , 2008, The Prostate.

[18]  M. Gleave,et al.  GLI2 Knockdown Using an Antisense Oligonucleotide Induces Apoptosis and Chemosensitizes Cells to Paclitaxel in Androgen-Independent Prostate Cancer , 2008, Clinical Cancer Research.

[19]  H. Klocker,et al.  Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer , 2004, Prostate Cancer and Prostatic Diseases.

[20]  G. Tuszynski,et al.  The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis , 2009, Pathology Oncology Research.

[21]  A. Murakami,et al.  Expression and function of fibroblast growth factor-inducible 14 in human corneal myofibroblasts. , 2009, Experimental eye research.

[22]  D. Tindall,et al.  Androgen receptor signaling in androgen-refractory prostate cancer. , 2001, Journal of the National Cancer Institute.

[23]  H. Kung,et al.  Impairment of the DNA Repair and Growth Arrest Pathways by p53R2 Silencing Enhances DNA Damage–Induced Apoptosis in a p53-Dependent Manner in Prostate Cancer Cells , 2008, Molecular Cancer Research.

[24]  K. Shiraki,et al.  Functional expression of TWEAK in human hepatocellular carcinoma: possible implication in cell proliferation and tumor angiogenesis. , 2004, Biochemical and biophysical research communications.

[25]  D. Lauffenburger,et al.  Calpain-2 as a target for limiting prostate cancer invasion. , 2003, Cancer research.

[26]  M. Berens,et al.  The Tumor Necrosis Factor-like Weak Inducer of Apoptosis (TWEAK)-Fibroblast Growth Factor-inducible 14 (Fn14) Signaling System Regulates Glioma Cell Survival via NFκB Pathway Activation and BCL-XL/BCL-W Expression* , 2005, Journal of Biological Chemistry.

[27]  H. Cunliffe,et al.  Role of TWEAK and Fn14 in tumor biology. , 2007, Frontiers in bioscience : a journal and virtual library.

[28]  G. Hostetter,et al.  Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB and correlate with poor patient outcome. , 2006, Cancer research.

[29]  T. Zheng,et al.  Tweak induces mammary epithelial branching morphogenesis , 2005, Oncogene.

[30]  J T Arnold,et al.  Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. , 2002, Endocrine-related cancer.

[31]  E. Montgomery,et al.  Identification of Fn14/TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma , 2007, International journal of cancer.

[32]  J. Tschopp,et al.  Interactions of Tumor Necrosis Factor (TNF) and TNF Receptor Family Members in the Mouse and Human* , 2006, Journal of Biological Chemistry.

[33]  V. Firlej,et al.  Role of cationic channel TRPV2 in promoting prostate cancer migration and progression to androgen resistance. , 2010, Cancer research.

[34]  N. Copeland,et al.  The Mitogen-inducible Fn14 Gene Encodes a Type I Transmembrane Protein that Modulates Fibroblast Adhesion and Migration* , 1999, The Journal of Biological Chemistry.